NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

Equality impact assessment – Guidance development

VibraTip for testing vibration perception to detect diabetic peripheral neuropathy

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?
No equality issues were identified during the scoping process.

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the Committee addressed these?
No potential equality issues have been identified. No equality issues were identified at the Committee meeting but it was noted that people with diabetes are covered under the 2010 Equality Act. Diabetic neuropathy is more common with increasing age and males may develop DPN earlier than females, but neuropathic pain causes more morbidity in females than in males. More secondary complications from diabetic neuropathy have been shown to occur in people of Hispanic or African American family origin.

3. Have any other potential equality issues been identified by the Committee and, if so, how has the Committee addressed these?
No potential equality issues have been identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?
The preliminary recommendations do not hinder access to the technology for any specific group.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No potential adverse impact has been identified.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the Committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?
No equality issues have been identified.

Approved by Associate Director (name): Mark Campbell

Date: 4/7/2014

Medical technologies guidance document

1. Have any additional potential equality issues been raised during the

consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during the consultation.

2.   If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations were not changed following consultation, other than editing for clarification. The final recommendations do not restrict access to the device by any specific group.

3.   If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No potential adverse impact has been identified.

4.   If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No barriers, difficulties or other equality issues have been identified.

5.   Have the Committee's considerations of equality issues been described in the medical technologies guidance document, and, if so, where?

No equality issues have been identified.

Approved by Programme Director (name): Mirella Marlow

Date: 19/12/14